Cargando…
Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
Tumor lysis syndrome (TLS) is widely recognized as a serious adverse event associated with the cytotoxic therapies primarily used in hematologic cancers, such as Burkitt lymphoma and acute lymphoblastic leukemia. In recent years, TLS has been more widely observed, due at least in part to the availab...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544586/ https://www.ncbi.nlm.nih.gov/pubmed/23237230 http://dx.doi.org/10.1186/1756-8722-5-75 |